Search Results - "Viens, P"

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer by M-Rabet, M., Cabaud, O., Josselin, E., Finetti, P., Castellano, R., Farina, A., Agavnian-Couquiaud, E., Saviane, G., Collette, Y., Viens, P., Gonçalves, A., Ginestier, C., Charafe-Jauffret, E., Birnbaum, D., Olive, D., Bertucci, F., Lopez, M.

“…Triple-negative breast cancers (TNBCs) are associated with a poor prognosis. In contrast to other molecular subtypes, they have no identified specific target…”
Get full text

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment by Dawood, S., Merajver, S.D., Viens, P., Vermeulen, P.B., Swain, S.M., Buchholz, T.A., Dirix, L.Y., Levine, P.H., Lucci, A., Krishnamurthy, S., Robertson, F.M., Woodward, W.A., Yang, W.T., Ueno, N.T., Cristofanilli, M.

“…Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis…”
Get full text

Construction and preliminary validation of a tool to measure the needs of adolescents and young adults (AYA) diagnosed with cancer: the QUestionnaire nEEd Cancer AYAs: QUEEC-AYAs by Justafré, S, Marino, P, Touzani, R, Dupeyre-Alvarez, F, Dantin, P, Viens, P, Vey, N, Calvin, S

“…In France, 2300 adolescents and young adults (AYAs, 15-25 years old) are diagnosed with cancer each year. As soon as the disease is diagnosed, a number of…”
Get full text

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer by Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., Esterni, B., Genre, D., Moureau-Zabotto, L., Giovannini, M., Seitz, J-F., Delpero, J-R., Turrini, O., Viens, P., Raoul, J-L.

“…Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of…”
Get full text

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab by Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., Proudhon, C., Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., Viens, P.

“…We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective…”
Get full text

Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? by Sabatier, R., Eymard, J.C., Walz, J., Deville, J.L., Narbonne, H., Boher, J.M., Salem, N., Marcy, M., Brunelle, S., Viens, P., Bladou, F., Gravis, G.

“…Sunitinib is a standard of care for metastatic renal cell carcinoma (mRCC). Hypothyroidism is frequently observed under sunitinib therapy. This study was…”
Get full text

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival by Bertucci, F., Ueno, N.T., Finetti, P., Vermeulen, P., Lucci, A., Robertson, F.M., Marsan, M., Iwamoto, T., Krishnamurthy, S., Masuda, H., Van Dam, P., Woodward, W.A., Cristofanilli, M., Reuben, J.M., Dirix, L., Viens, P., Symmans, W.F., Birnbaum, D., Van Laere, S.J.

“…Inflammatory breast cancer (IBC) is an aggressive disease. To date, no molecular feature reliably predicts either the response to chemotherapy (CT) or the…”
Get full text

The mutational profile of IBC reveals higher mutational burden, deficiency of homologous recombination and NOTCH signalling by Van Laere, S.J., Finetti, P., Rypens, C., Birnbaum, D., Vermeulen, P., Viens, P., Dirix, L.Y., Bertucci, F.

Get full text

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France by Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.

“…The impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer…”
Get full text

Aqua polo: Preliminary feasibility and efficacy study of a programme of adapted, supervised water polo to reduce fatigue and improve women's psychological and social recovery after breast cancer treatment: A mixed-methods design by Cuvelier, S., Goetgheluck-Villaron, C., Cohen, M., Tallet, A., Berline, M., Boher, J.M., Jowett, S., Justafré, S., Dantin, P., Viens, P., Calvin, S.

“…Physical activity has been shown to have many benefits, including reducing cancer-related fatigue (CRF) and improving psychological and physical recovery from…”
Get full text

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer by Ligthart, S.T., Bidard, F.-C., Decraene, C., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Viens, P., Pierga, J.-Y., Terstappen, L.W.M.M.

“…Circulating tumor cells (CTCs) can provide the basis for a liquid biopsy and may guide the use of targeted therapies. We report on unbiased quantification of…”
Get full text

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer by Goncalves, A, Fabbro, M, Lhommé, C, Gladieff, L, Extra, J.-M, Floquet, A, Chaigneau, L, Carrasco, A. Tisseron, Viens, P

“…Abstract Background. Cancer of the cervix occurs in ∼ 500 000 women worldwide each year, with prognosis highly dependent on disease stage at diagnosis…”
Get full text

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy by GONCALVES, A, ESTERNI, B, MENG, X.-Y, FUNG, E. T, BIRNBAUM, D, MARANINCHI, D, VIENS, P, BORG, J.-P, BERTUCCI, F, SAUVAN, R, CHABANNON, C, CUBIZOLLES, M, BARDOU, V. J, HOUVENAEGEL, G, JACQUEMIER, J, GRANJEAUD, S

“…A total of 30-50% of early breast cancer (EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite…”
Get full text

A seven-gene prognostic model for platinum-treated ovarian carcinomas by Sabatier, R, Finetti, P, Bonensea, J, Jacquemier, J, Adelaide, J, Lambaudie, E, Viens, P, Birnbaum, D, Bertucci, F

“…Background: Prognosis of ovarian carcinoma is poor, heterogeneous, and not accurately predicted by histoclinical features. We analysed gene expression profiles…”
Get full text

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation by Boudin, L, Gonçalves, A, Sabatier, R, Moretta, J, Sfumato, P, Asseeva, P, Livon, D, Bertucci, F, Extra, J-M, Tarpin, C, Houvenaegel, G, Lambaudie, E, Tallet, A, Resbeut, M, Sobol, H, Charafe-Jauffret, E, Calmels, B, Lemarie, C, Boher, J-M, Viens, P, Eisinger, F, Chabannon, C

“…Breast cancer carrying BRCA mutation may be highly sensitive to DNA-damaging agents. We hypothesized a better outcome for BRCA-mutated (BRCA mut ) metastatic…”
Get full text

2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres by Gilabert, M, Rho, Y.S, Kavan, T, Chanez, B, Mamo, A, Barrera, I, McLean, J, Viens, P, Batist, G, Kavan, P

Get full text

2354 Is pancreatic adenocarcinoma more aggressive in adolescents and young adults? A multi-institute retrospective study by Gilabert, M, Rho, Y.S, Megdanova, V, Mihaylova, Z, Rahal, S, Viens, P, Batist, G, Kavan, P

Get full text

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer by Gonçalves, A., Pierga, J.-Y., Ferrero, J.-M., Mouret-Reynier, M.-A., Bachelot, T., Delva, R., Fabbro, M., Lerebours, F., Lotz, J.-P., Linassier, C., Dohollou, N., Eymard, J.-C., Leduc, B., Lemonnier, J., Martin, A.-L., Boher, J.-M., Viens, P., Roché, H.

“…Inflammatory breast cancer (IBC) is a rare and aggressive disease requiring a multimodal treatment. We evaluated the benefit of adding docetaxel–5-fluorouracil…”
Get full text

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients by Bertucci, F., Finetti, P., Roche, H., Le Doussal, J.M., Marisa, L., Martin, A.L., Lacroix-Triki, M., Blanc-Fournier, C., Jacquemier, J., Peyro-Saint-Paul, H., Viens, P., Sotiriou, C., Birnbaum, D., Penault-Llorca, F.

“…The genomic grade index (GGI) completes the prognostic value of histological grade (HG). Other proliferation markers include the mitotic activity index (MAI)…”
Get full text

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer by Gravis, G., Bladou, F., Salem, N., Gonçalves, A., Esterni, B., Walz, J., Bagattini, S., Marcy, M., Brunelle, S., Viens, P.

“…Erlotinib is an orally active small-molecule tyrosine kinase inhibitor targeted against human epidermal growth factor receptor 1/epidermal growth factor…”
Get full text